Company Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Jiangsu Yahong Meditech Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
5.29 ^CNY	+4.13%		+4.34%	-50.93%

Jun. 25	Yahong Meditech to Trial Drug Against Amoebae Infection	MT
Jun. 17	ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals	CI

Jiangsu Yahong Meditech Co Ltd is a China-based company mainly engaged in drug research and development (R&D). The Company focuses on innovative drugs in the field of urogenital tumors and other major diseases. The product pipelines being developed by the Company include APL-1202, APL-1501, APL-1706, APL-1702, ASN-1764, ASN-1780, APL-1901, APL-1401, ASN-1733 and others. The Company is still in the R&D stage.

Number of employees: 394

CNY in Million	2022	Weight	2023	Weight	Delta
Anti-tumor 68.1 %	-	-	9	68.1 %	-
Other 16.2 %	-	-	2	16.2 %	-
Data Authorization Permission 15.7 %	-	-	2	15.7 %	-

CNY in Million	2022	Weight	2023	Weight	Delta
China 68.1 %	0	100.0 %	9	68.1 %	+35,795.13%
Overseas 31.9 %	-	-	4	31.9 %	-

Managers	Title	Age	Since
Ke Pan CEO	Chief Executive Officer	56	10-03-15
Ming Yuan Yang DFI	Director of Finance/CFO	41	20-12-10
Cheng Feng Zhuang COO	Chief Operating Officer	61	19-07-10
Xin Ming Jiang BRD	Director/Board Member	54	21-01-24

Members of the board	Title	Age	Since
Bing Hui Zhang BRD	Director/Board Member	61	20-12-10
Xin Ming Jiang BRD	Director/Board Member	54	21-01-24
Ke Pan CEO	Chief Executive Officer	56	10-03-15
Cheng Feng Zhuang COO	Chief Operating Officer	61	19-07-10
Bin Huang BRD	Director/Board Member	57	20-12-10
Yi Zhong CHM	Chairman	51	20-12-10
Xian Xian Li BRD	Director/Board Member	35	20-12-10
Ming Yuan Yang DFI	Director of Finance/CFO	41	20-12-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	570,000,000	311,741,460 ( 54.69 %)	0	54.69 %

Name	Equities	%	Valuation
Beijing Longpan Investment Management Consulting Center GP 12.25 %	34,629,054	12.25 %	24 M ¥
HuaAn Fund Management Co., Ltd. 7.396 %	20,900,166	7.396 %	15 M ¥
Jue Sun 5.447 %	15,391,333	5.447 %	11 M ¥
Qiming Venture Partners Ltd. 4.780 %	13,506,045	4.780 %	9 M ¥
Shenzhen Guozhong Venture Capital Management Co. Ltd. 4.283 %	12,102,586	4.283 %	9 M ¥
Hangzhou Kaitai Capital Management Co. Ltd. 3.501 %	9,894,015	3.501 %	7 M ¥
China Asset Management Co., Ltd. 2.397 %	6,773,293	2.397 %	5 M ¥
Penghua Fund Management Co., Ltd. 2.110 %	5,961,125	2.110 %	4 M ¥
Yinhua Fund Management Co., Ltd. 1.523 %	4,303,698	1.523 %	3 M ¥
Zhonghai Fund Management Co., Ltd. 1.263 %	3,568,067	1.263 %	3 M ¥

Jiangsu Yahong Meditech Co., Ltd.

19/F, Building B Lane 221, Dongyu Road

200126, Shanghai

http://www.asieris.cn

address Jiangsu Yahong Meditech Co., Ltd.(688176)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.29 CNY

Average target price

12.28 CNY

Spread / Average Target

+132.23%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
JIANGSU YAHONG MEDITECH CO., LTD.	-50.93%	415M
VERTEX PHARMACEUTICALS INCORPORATED	+20.95%	127B
REGENERON PHARMACEUTICALS, INC.	+23.00%	117B
ARGENX SE	+25.15%	27.77B
BIONTECH SE	-19.75%	20.44B
GENMAB A/S	-16.57%	16.62B
BEIGENE, LTD.	-16.56%	15.92B
NEUROCRINE BIOSCIENCES, INC.	+11.19%	14.74B
WUXI APPTEC CO., LTD.	-46.65%	14.94B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs